StonkScan
OverviewRevenueFinancialsValuationOutlookOwnership
Price
Performance · vs S&P 500
Company
Eli Lilly and Company
NYSE · USD
Mega cap
1.21× peer median
2.40× peer median
49% less volatile
$16.2B of free cash flow against $48.3B of net income across 5 fiscal years.
Quality · FY25
$35.2B of net debt against $16.8B of annual operating cash flow.
Liquidity · FY25
Free cash flow of $9.0B covers the business without outside capital, on $7.3B of cash and short-term investments.
Liquidity · FY25
$55.6B of current assets against $35.2B due within a year.
Liquidity · FY25
Eli Lilly's tirzepatide is showing potential across autoimmune diseases. The medicine could earn additional indications and attract broader insurance coverage over time.
Aspen Pharmacare expects African sales of Eli Lilly's blockbuster weight-loss and diabetes drug Mounjaro to exceed 2 billion rand ($124 million) in its current financial year, buoyed by surging demand in South Africa and planned launches in Nigeria and Kenya.
Average month-end to month-end move for LLYin each calendar month. Point at a bar for that month's spread: past seasonality is a tendency in a small sample, not a forecast.
+$20.1B vs FY24
FY24 → FY25
FY21 → FY25, annualized
+49.6% vs the four before
Q2 FY26 · +47.7% YoY
+44.7% YoY
+2.5 pp YoY
+6.7 pp YoY
+94.9% YoY
+8.2 pp YoY
+95.6% YoY
+2065.6% YoY
−$5.0B YoY
P/E vs EPS growth · below the channel = cheaper for its growth
P/S vs revenue growth · below the channel = cheaper for its growth
| Ticker | P/E | Fwd P/E | PEG | P/S | Fwd P/S | PSG | EPS gr | Rev gr |
|---|---|---|---|---|---|---|---|---|
| LLY | 38.8 | 31.9 | 0.98 | 13.7 | 12.4 | 0.61 | 33% | 20% |
| JNJ | 32.2 | 24.0 | 2.70 | 6.9 | 6.6 | 0.88 | 9% | 8% |
| ABBV | 73.3 | 18.6 | 0.19 | 7.1 | 6.8 | 0.77 | 96% | 9% |
| MRK | 120.9 | 55.4 | 4.26 | 5.7 | 5.6 | 1.22 | 13% | 5% |
| NVS | 24.3 | 18.6 | 1.30 | 5.6 | 5.4 | 0.92 | 14% | 6% |
| AZN | 24.5 | 16.1 | 0.65 | 4.2 | 4.0 | 0.56 | 25% | 7% |
Dots = reported EPS vs consensus · gap = surprise · dashed = estimate ($)
Last 12M · $100M bought · $79M sold · net +$21M
$65.2B of revenue against $35.5B of operating costs, leaving $29.7B.
Profitability · FY25
28.0% in FY21 to 45.6% in FY25.
Profitability · FY25
$28.3B in FY21 to $65.2B in FY25, with the latest year up 44.7%.
Growth · FY25
Revenue came in above consensus by 9.6% on average over the last four reports.
Quality · Aug '26
Eli Lilly just delivered one of the biggest quarters in Big Pharma history, yet the stock sits well below its 52-week high. A closer look at the pipeline and valuation reveals why the real opportunity may still be ahead.
Share of the latest fiscal year, largest first. The line is the segment across every fiscal year we have: hover it to read one.
What each segment added to or took off the top line in dollars: ranked by the size of the move, not its percentage.
| $ billions | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|
| Cash & equivalents | 7.2 | 3.3 | 2.8 | 2.1 | 3.8 |
| Short-term investments | 0.1 | 0.2 | 0.1 | 0.1 | 0.1 |
| Receivables | 20.2 | 13.3 | 11.3 | 8.6 | 8.1 |
| Inventory | 13.7 | 7.6 | 5.8 | 4.3 | 3.9 |
| Total current assets | 55.6 | 32.7 | 25.7 | 18.0 | 18.5 |
| Property, plant & equipment | 24.7 | 17.1 | 12.9 | 10.1 | 9.0 |
| Long-term investments | 2.8 | 3.2 | 3.1 | 2.9 | 3.2 |
| Other non-current assets | 29.4 | 25.7 | 22.3 | 18.4 | 18.2 |
| Total assets | 112.5 | 78.7 | 64.0 | 49.5 | 48.8 |
| Accounts payable | 5.4 | 3.2 | 2.6 | 1.9 | 1.7 |
| Short-term debt | 1.6 | 5.1 | 6.9 | 1.5 | 1.5 |
| Total current liabilities | 35.2 | 28.4 | 27.3 | 17.1 | 15.1 |
| Long-term debt | 40.9 | 28.5 | 18.3 | 14.7 | 15.3 |
| Total liabilities | 85.9 | 64.4 | 53.1 | 38.7 | 39.7 |
| Shareholders’ equity | 26.5 | 14.2 | 10.8 | 10.6 | 9.0 |
Fiscal year · latest five reported years
| $ billions | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|
| Operating cash flow | 16.8 | 8.8 | 4.2 | 7.6 | 7.4 |
| Capital expenditure | −7.8 | −8.4 | −7.4 | −3.0 | −2.0 |
| Free cash flow | 9.0 | 0.4 | −3.2 | 4.6 | 5.4 |
| Investing cash flow | −11.0 | −9.3 | −7.2 | −3.8 | −2.9 |
| Dividends paid | −5.4 | −4.7 | −4.1 | −3.5 | −3.1 |
| Share buybacks | −4.1 | −2.5 | −0.8 | −1.5 | −1.3 |
| Net debt issued / (repaid) | 8.1 | 8.9 | 8.6 | −0.1 | 0.5 |
| Financing cash flow | −2.2 | 1.2 | 3.5 | −5.4 | −4.1 |
| Net change in cash | 4.0 | 0.4 | 0.8 | −1.8 | 0.2 |
Fiscal year · outflows shown negative
Solid = reported · dashed = forward consensus · shaded = analyst low–high ($B)
Rows: discount rate (r) · Columns: terminal growth (g∞) · cell = fair value, shaded by up/downside vs 1160.